Guest blog: The Biotech Bull and its impact on the future of Regenerative Medicine

‘Alternative financing models' by Dr. Navid Malik As head of life sciences research at Cenkos securities and with a background in science, Dr. Malik’s words carried bullish weight as he assured there's a 10 year bull market in Biotech just around the corner.  Whilst being what any stem cell researcher and regenerative medicine financer wants to hear the reference was …

Study highlights lack of VC funding in emerging markets

A recent article in Nature Biotechnology highlighted a lack of venture capital (VC) funding in certain emerging markets. The authors estimated that from 2000 to 2012, innovative VC and PE financing for Chinese, Indian, Brazilian and South African research-based companies totalled $1.7 billion – this is in comparison to the $1.1 billion of VC investment US research companies received in …

Seed funding start-ups in Emerging Technologies: perspectives on cell therapeutics

Syndicate Innovation Venturing: “Bringing together actors from complementary economic sectors in a ‘non-zero sum game' partnership to conduct seed funding in technology areas with blockbuster potential” Alain Vertes, General Managing Partner & Co-founder at Park BioVentures (and previous Global Alliance Director at Roche) delivered a presentation at the 2012 World Stem Cells & Regenerative Medicine Congress to discuss strategic biotech …